MARKETING ANALYSIS OF NSAID OF OXYCAM GROUP IN THE KYRGYZ REPUBLIC

Abstract

The article shows the results of a marketing analysis of non-steroidal anti-inflammatory medicines (NSAIMs) of the oxycam group in the Kyrgyz Republic. The results of the study revealed that the Kyrgyz pharmaceutical market has forty trade names (TN) of NSAIMs of the oxycam group, where the majority are meloxicam (MO1AC06), 29 TN of medicines (72,5%), and tenoxicam (M01AC02), 7 TN medicines (17,5%). Studies have shown that among manufacturers of drugs of these groups, medicines from non-CIS countries are leading, more than half - 57,5%, where Turkey takes the first place. The countries of the near abroad account for 32,5% of medicines, and for medicines of domestic production - 10%. In the Kyrgyz Republic, medicines manufactured in 13 countries of the world are registered, while NSAIMs of the oxycam group, which are produced in the Eurasian Union countries, account for 27,5%. Among oxycams, solid dosage forms are mainly represented, the specific gravity of which is 67,5%. Most of the NSAIMs from the oxycam group are in the mid-price segment.